aTYR PHARMA INC
aTyr Pharma, Inc. (Nasdaq: ATYR) is a clinical-stage biotechnology company developing biologic therapies for fibrosis and inflammation using a discovery platform based on extracellular biology of tRNA synthetases. Its lead candidate, efzofitimod, is in development for interstitial lung diseases, including pulmonary… From the company’s description.
Over the twelve months to Sep 30, 2026, aTYR PHARMA INC reported a net loss of $53.32M. Operations used $43.58M in cash. In fiscal 2025, it reported revenue of $0.19M, down 19.1% from fiscal 2024, and a net loss of $74.12M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What aTYR PHARMA INC does
In the company’s own words
aTyr Pharma, Inc. (Nasdaq: ATYR) is a clinical-stage biotechnology company developing biologic therapies for fibrosis and inflammation using a discovery platform based on extracellular biology of tRNA synthetases. Its lead candidate, efzofitimod, is in development for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-associated ILD; the company is also evaluating it in a Phase 2 study in SSc-ILD. Additional preclinical candidates include ATYR0101, a fusion protein being studied for fibrotic diseases, and ATYR0750, a candidate targeting FGFR4. The company’s research also uses a proprietary library of domains derived from all 20 tRNA synthetases to identify potential drug candidates. aTyr has an exclusive Japan development and commercialization agreement for efzofitimod with Kyorin Pharmaceutical, which funds activities there, while aTyr supplies drug product and supports development. The company is pre-commercial and reports its operations as a single business. Its website is https://www.atyrpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1339970
- SIC
- 2836
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns aTYR PHARMA INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · aTYR PHARMA INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do aTYR PHARMA INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of aTYR PHARMA INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in aTYR PHARMA INC's last four quarterly filings that the numbers alone won't show?”